Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Investors Business Daily
Investors Business Daily
Business
INVESTOR'S BUSINESS DAILY and JULIE MAK

Eli Lilly Stock Shows Improved Relative Price Performance; Still Shy Of Benchmark

On Tuesday, Eli Lilly stock got an upgrade to its Relative Strength (RS) Rating, from 68 to 74.

When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.

IBD's proprietary rating tracks share price movement with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the trailing 52 weeks compares to all the other stocks in our database.

Decades of market research reveals that the best stocks typically have an RS Rating of above 80 in the early stages of their moves. See if Eli Lilly stock can continue to rebound and hit that benchmark.

See How IBD Helps You Make More Money In Stocks

Is Eli Lilly Stock A Buy?

Eli Lilly stock is trying to complete a consolidation with a 384.54 entry. See if the stock can clear the breakout price in heavy trading.

The medical company reported negative growth for both the top and bottom lines last quarter.

Eli Lilly stock earns the No. 2 rank among its peers in the Medical-Diversified industry group. Eli Lilly and Danaher are also among the group's highest-rated stocks.

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.